Welcome to the Sanara MedTech Inc. Q3 2021 results and business update. At this time, all participants have been placed on a listen-only mode, and the floor will be opened for questions and comments after the presentation. If you have a question or comment at any time, you may press star one to join the queue. If your question has been answered and you no longer wish to ask it, you may press star two to be withdrawn from the queue. It is now my pleasure to turn the floor over to your host, Callon Nichols, Director of Investor Relations. Sir, the floor is yours. Thank you, and good morning, everyone. I'd like to welcome you to Sanara MedTech's earnings conference call for the quarter ended September 30, 2021. We issued our earnings release Friday afternoon, and I would also like to highlight that we will post a link to today's deck on our investor relations page. This supplemental deck, as well as a copy of the earnings release, the 10-Q, and a transcript of this call will be available on this page. We will reference this information in our remarks today. We expect today's prepared comments from Ron Nixon, Executive Chairman, Mike McNeil, Chief Financial Officer, and Zach Fleming, President, Surgical, to last approximately 15 minutes to allow time for Q&A. Certain statements in this conference call and our press release and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risk and uncertainties involving forward-looking statements and factors that could cause actual results to vary from those projected or implied by forward-looking statements, please see our most recent Form 10-Q and annual report on Form 10-K. Now, I'd like to turn the call over to Ron. Thank you, Callon, and good morning, everyone. I'll begin with an overview of the Q3, and then we'll provide an in-depth discussion for each of the subsequent slides that were given to you. Sanara generated $5.8 million in revenue and a net loss of $2 million in the Q2 of 2021. Despite an impact from the COVID-19 Delta variant in key large markets, including Texas and the Northeast, this was the second-best revenue quarter for the company in history and was driven by surgical product sales. Our net loss was largely driven by an increase in SG&A, which was $1.8 million higher than Q3 2020. Approximately 70% or $1.3 million of this increased SG&A was due to increased direct sales and marketing costs related to the expansion of our surgical sales force, as well as higher commissions due to higher product sales. The Rochal asset acquisition, which we completed in Q3, contributed approximately $260,000 of incremental SG&A when compared to Q2 of 2021, adjusted for a one-time reclassification of R&D expense in Q3. These were planned expenses to expand our sales force and research and development capabilities to further advance our six focus areas. The surgical team has continued to focus on adding high-quality experienced regional and territorial sales managers to our team, obtaining hospital approvals, product adoption, and introducing new products. Zach will discuss the specifics in his remarks this morning. We continue to see additional opportunities for our products in surgery and are continuing our pursuit of clinical evidence for outcomes. In the Q3, we continued introducing our telemedicine and virtual care business of WounDerm. We executed an agreement and launched a pilot in home healthcare market to prove the efficacy of WounDerm solutions and demonstrate the company's overall value proposition related to cost and outcomes of our comprehensive wound and skin strategy. As part of this pilot, the company's EMR was adapted for home healthcare market, and we concurrently signed a distribution agreement for our proprietary products with that firm. For our virtual consult services, our wound care group, Mg roup, is now licensed to provide wound care virtual consults in 48 states, and we expect to be licensed in all 50 states by the end of the year. We are currently having discussions with a number of value-based and managed care companies and are exploring possibilities across all segments of the post-acute and acute settings. A critical component of our strategy is our partnership with Precision Healing. They are now making considerable progress and expect to file a 510(k) for the Precision Healing Imager by the end of the year. As you know, Rochal Technologies is now part of Sanara, and we're working closely with them on our product pipeline with a focus on bringing next-generation Cellerate and HYCOL to the market, as well as BIASURGE, our sterile antimicrobial cleanser for the surgical market. Now I'll turn it over to Zach Fleming to discuss our surgical business. Thanks, Ron. Our surgical division continues to grow in terms of sales, hospital approvals, and the size of our team. In the Q3, we added people to our sales team, bringing the total to 29 regional and territory sales managers. We continued to see growth in our distributor partnerships and increased both the number of teams and individuals representing our products. At the end of Q3, CellerateRX had been sold in over 395 hospitals and ambulatory surgery centers across 21 states, and it was approved to be sold in approximately 990 facilities. As we've discussed before, we believe there are approximately 12,000 hospitals and ambulatory surgery centers in the United States where CellerateRX could potentially be used. In Q3, we continued to see strong demand for and interest in our products. We faced headwinds in a few of our key markets in Texas and the Northeast. Due to the COVID-19 Delta variant surge. However, as with previous surges, we believe that the majority of these procedures were postponed and will eventually be performed. Year-over-year, we have seen some headwinds due to cost per case, but we are working to mitigate the impact of this through win-win contracting opportunities in those facilities. Subsequent to the end of the quarter, we announced the commercial launch of two new products that we have licensed from Cook Biotech, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix. Adding products to our surgical bag has been a strategic goal of ours and should allow us to increase our operating profit as these products begin to generate revenue for the company. I'll now turn it over to our CFO, Mike McNeil, to discuss our Q3 financial results. Thanks, Zach. During the Q3, we generated revenues of $5.8 million compared to revenues of $4.3 million for the Q3 of 2020, representing a 35% increase from the prior year. Year to date through September 30, 2021, revenues totaled $17.1 million compared to revenues of $10.8 million for the same period last year, which represented a 58% increase over the prior year period. The higher revenues in 2021 were primarily due to the increased penetration of surgical wound care products by our sales force additions last year and our continuing presence strategy to expand our independent distribution network in both new and existing U.S. markets. As Zach discussed, we have faced some headwinds due to the COVID-19 Delta variant and cost per case concerns. We had a net loss of $2 million for the Q3 of 2021 compared to the net loss of $1.2 million for the Q3 of 2020. The higher net loss in the Q3 of 2021 was primarily due to higher SG&A expenses, which were approximately $1.8 million higher than prior year, partially offset by higher Q3 gross profit, which was $1.4 million higher than the same period in 2020. Q3 depreciation, amortization, and other expenses collectively were approximately $400,000 higher compared to prior year. For the nine months into September 30, 2021, we had a net loss of $4.4 million compared to the net loss of $4.2 million for the same period of 2020. The higher net loss for the nine months ended September 30, 2021, was primarily due to higher SG&A, partially offset by higher revenues. The higher SG&A expenses in 2021 were primarily driven by increased selling costs as a result of sales force expansion and higher sales commissions due to higher product sales. Finally, looking at our balance sheet, we ended the Q2 in a strong financial position with $22.4 million of cash on hand. I will now turn it back over to Ron for a few closing comments. Thank you, Mike. As we've discussed historically, our goal at Sanara MedTech is to offer a comprehensive wound and skin care strategy that can help providers and patients treat wound and skin conditions in any care setting. In the Q3, we continued to advance that goal by increasing penetration in the surgical wound care market, adapting our EMR to the home healthcare vertical, and executing and launching a pilot for our virtual consult services with a major home healthcare company while simultaneously pursuing other pilots. We continue to seek opportunities to expand and improve our overall strategy. That concludes this quarter's comments, and we look forward to answering any questions you may have. Operator, we're ready to open the call for questions. Thank you. Thank you. Ladies and gentlemen, the floor is now open for questions. If you have any questions or comments, please press star one on your phone at this time. If you would like to withdraw from the queue, you may press star two. We do ask that if you are listening via speakerphone, to please pick up your handset for optimum sound quality. Once again, if you have any questions or comments, please press star one on your phone now. Please hold a moment while we poll for questions. Once again, if you have any questions or comments, please press star one now. Our first question today is coming from Ian Cassel at MicroCapClub. Your line is live. You may begin. Yeah, I guess the question I would have is on the two new products from Cook Biotech. Are those products? Do you expect those to be material to the company in 2022, or do you think that's more of a, you know, 2023 or 2024 materiality on those two products? Yeah. Ian, this is Ron Nixon. I'll turn that over to Zach. And Zach, if you don't mind, you can share with them your thoughts on when these will be penetrating the market. Sure. So we believe that they are good, very good products. We already seen some adoption with the FORTIFY products. I do believe they'll produce a reasonable amount of revenue next year. As you know, there's some difficulties in getting products approved, but we're in the midst of that right now, gaining some approvals in different facilities, doctor trials, and those trials are going very positive. Thank you. Maybe a follow-up. I see that you're up to, I think, 29 RSMs. I was wondering where do you see that kind of peaking out to hit all 50 states? I think we need coverage across all 50 states. We are doing this TM model. I think you guys have heard about that. That's the territory manager model where we get higher penetration in each market. With that model, we're starting to see that there's some great legs to that. We're seeing great expansion within those facilities. And so that number kind of evolves into somewhere between 40 and 50, we believe, total number of heads. And that's really dependent on, you know, our ability to get into facilities and create kind of a broad network of doctors within that facility. And those TMs are doing a good job of that. I think it's gonna be in that 40-50 range, roughly one per state, obviously a little higher density in the Northeast. But I think, Ian, to your point, the regional sales managers, we have found that we're able to get leverage off of them, and they can cover more than one state. So as Zach mentioned, that's the combination of Territory and regional sales managers. Great clarification. Yes. Okay, thank you. Maybe just a follow-up. I saw that you're gonna have your submission filed for the 510(k) for Precision Healing. You know, what's the timeline, you know, for approval in a product like that? And you know, it seems in previous slide decks, it seems like that product or that diagnostic is a real competitive advantage to the company, you know, nothing like it on the market. Yeah. Thank you, Ian. We actually do believe it has very competitive advantage to it. It provides more data with the biomarkers that we've identified than any other device that we know of in the market. As to how long it will take, historically, it had been 90 days or less to receive FDA approval on a device like this. With today's COVID impact and just hiring impact, the FDA has been constrained, and we've seen a slowness in their approval process, and it's been very hard to predict. But we're hopeful that we will have it by the end of the Q2. What is the form factor like of that product? Is it sort of like an iPhone looking device? Or how should somebody, you know, think about it? Yeah. It's the original prototype was a little bit larger than an iPhone, and the thickness of it is a little larger because of the room that you need for the lenses and the filters that are on that camera. Over time, we see that adopting into a different form factor that potentially could be smaller and easier to use, and that's what our engineers are working on now for that next generation already. Okay. And then I think within your prepared remarks, you mentioned BIASURGE. You know, can you talk about the potential of that product and when you'd expect that to have to be on market? Yeah. Zach, I'll let you take that. Sure. We think there's a great potential there. Medicated washes are kind of a new thing in the hospitals. You'll see a few different market entrants in there already. And, you know, what they're looking for in a hospital is consistency and obviously another way to battle some downstream infection problems in the surgical space. So when they put an implant in, they're trying to reduce bacterial seeding as well as any kind of deep infection. So this type of a product is very useful in you know, washing the surgical area, the cavity, and then obviously rinsing it out and then putting it you know, closing the wound. So we think it's a really good opportunity. We do think that that'll come into fruition towards the start of 2023. So we should get through everything and some additional testing, trials, approvals, everything by the end of this coming year, 2022. And Ian, we expect to have the same type of results that we have seen on our existing BIAKŌS product in terms of impact on bacteria. Okay. Maybe one last question. There's a lot of moving parts to the story, and you're working on a lot of things. I mean, looking out maybe even just 12 months, where do you hope to have the company positioned? Well, looking out 12 months, I would tell you that as it's obvious from the amount of capital that we have spent on our advanced wound care strategy, which involves all the component parts of the six focus areas beyond what surgical needs are. And then you look at the support of the virtual consult, our EMR that has been developed, and to be able to add skin as well. We see that the conversations with our managed care potential partners, home health, et cetera, should be evolving to where those are starting to have penetration into those markets within the next 12 months in a more significant way to offset some of the losses that we've incurred by spending ahead of the curve on advancing that strategy. Good. Thank you. Thanks for taking my questions. Mm-hmm. Thank you, Ian. Thank you. Ladies and gentlemen, if there will be any final questions or comments, please press star one now. Our next question is coming from Evan Claar at CBI Capital. Your line is live. You may begin. Thank you. Good morning. I have some somewhat remedial questions that maybe require some education. I'm interested in CellerateRX's traction in the marketplace, and I see the large number of hospitals approved against 395 hospitals using it in the quarter. Can you give us some inkling of the 395, how many are new and how many are repeat users from prior quarters, and what it costs per use or how much revenue you get per use? Yeah, Zach, I'll let you take that. And Zach, you can just, you know, a lot of that is already in the press release and some of the historical data, so you could just cite that to him, if you would. Yeah. Hi there. So $395, you know, it's roughly about a I believe 100 or so more than the previous quarter. Callon might have that right in front of him as far as the exact number, but we are making good headway there. You know, our goal of the 900 or so that is approved, you know, what we're really trying to do there is find those hospitals where there's a need, where they do have some, you know, patients that fit the type of patient, the profile that we're looking for. That's that patient that is, you know, comorbid and has a lot of different issues that might impact their healing. And so that's the type of hospital we're looking for and of course, looking for the surgeons that treat those patients. And so it is a little bit of kind of seek and find within those 990 hospitals. And as we start to do that, as we've been doing that, we're starting to expand both in those 400 hospitals, roughly, but as well into more hospitals. So that's really the goal of the whole thing. It's going very well, so we're really excited about that. It is a little bit of a needle in a haystack to try to find those patients. Not every hospital has those types of patients, as you know. Thank you. What I'm guessing is that we're seeing 1-2 uses per week per hospital on average. And is this a much smaller TAM or, you know, addressable market because you need people with these special ailments? I would- Can that rise materially? Yeah, I don't think probably describing it as a needle in a haystack is quite accurate because if you look at the population of people that are having hip replacement and having other types of ortho, spine surgery, et cetera, general surgery, when you start talking about the aging population and the look at how the baby boomers are aging, many of those patients have comorbidities. Then it's a matter of education to the surgeons to let them understand there is a product out there now that can help them with the healing aspect of these patients due to the high number of comorbidities that they have. Gotcha. And do you get about $700 in revenue per use? You know, we, we, we don't like to give out that number for many reasons, but I would just say, you know, you're in the ballpark. Okay. Thank you very much. Mm-hmm. Thank you. We have no further questions in queue at this time. I will now turn the floor back over to management for any closing remarks. We really appreciate everybody participating today. Thank you very much, and we look forward to continuing to do this in the future. Thank you all for being in attendance. Thank you, ladies and gentlemen, this does conclude today's event. You may disconnect at this time and have a wonderful day. We thank you for your participation.